צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Ascendis (ASND)

Ascendis Pharma A/S (ASND) is implementing the TransCon platform to replace daily injections with infrequent procedures. A technological moat and strong R&D ensure high product margins. Year-over-year sales growth (over 4 quarters) confirms the strategy's effectiveness, with the indicator remaining around 94.00. This trend helps the company capture the growth hormone market, radically transforming conventional drug delivery systems.
ascendispharma.com (ASND) - פילוחי מדדים ודוחות פיננסיים

For Ascendis Pharma A/S (ASND), the commercialization dynamics of long-acting drugs in the US and Europe directly determine the pace of business scaling. By analyzing the year-over-year revenue growth rate over the TTM, investors track the rolling sales increase, which allows them to identify a fundamental reversal in demand and confirm the stability of cash flows prior to official reports, thereby eliminating the risk of capital freeze.